Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

EXPLAINED: Global blood rapeutics | Vintage Vibes

Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2022

Benzinga · Aug 9, 2022

Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022

Benzinga · Aug 8, 2022

12 Health Care Stocks Moving In Thursday's Intraday Session

Benzinga · Aug 4, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Recap Of Tuesday's Biotech Catalysts - End of The Day Summary

European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis. AbbVie shares traded in a range of $150.33 to $153.56 on a day volume…

Benzinga · Jul 26, 2022

Looking Into Global Blood Therapeutics's Return On Capital Employed

According to Benzinga Pro data, during Q1, Global Blood Therapeutics (NASDAQ:GBT) posted sales of $55.16 million. Earnings were up 7.03%, but Global Blood Therapeutics still reported an overall loss of $81.42 million.

Benzinga · Jun 28, 2022

Sickle cell: Just half of nurses and doctors feel confident about treating illness, report finds

Exclusive: The experiences of more than 1,300 people people living with the illness, carers and healthcare professionals, were examined

The Independent UK · Jun 14, 2022

Global Blood Therapeutics Earnings Perspective: Return On Capital Employed

According to data from Benzinga Pro, during Q1, Global Blood Therapeutics's (NASDAQ:GBT) reported sales totaled $55.16 million. Despite a 7.03% increase in earnings, the company posted a loss of $81.42 million.

Benzinga · May 20, 2022

Read news from The Economist, FT, and more,
with one subscription

Recap: Global Blood Therapeutics Q1 Earnings

Global Blood Therapeutics (NASDAQ:GBT) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Benzinga · May 4, 2022

Looking Into Global Blood Therapeutics's Return On Capital Employed

Global Blood Therapeutics (NASDAQ:GBT) brought in sales totaling $56.10 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 23.37%, resulting in a loss of $87.58 million.

Benzinga · Apr 26, 2022

Coverage From

Organisations

Palantir Technologies

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Amyotrophic lateral sclerosis

35 stories

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.